Influence of drug transporters and stereoselectivity on the brain penetration of pioglitazone as a potential medicine against Alzheimer's disease

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Chang, Kai Lun ^a,b   Pee, Hai Ning ^a   Yang, Shili ^a   Ho, Paul C ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ABC TRANSPORTER; ABCG2 PROTEIN, MOUSE; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; MULTIDRUG RESISTANCE PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE;

AGONISTS; ALZHEIMER DISEASE; ANIMAL; BRAIN; CELL LINE; CHEMISTRY; DISEASE MODEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; METABOLISM; MOUSE; TANDEM MASS SPECTROMETRY; TISSUE DISTRIBUTION; TRANSPORT AT THE CELLULAR LEVEL;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; BRAIN; CELL LINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DISEASE MODELS, ANIMAL; MALE; MICE; P-GLYCOPROTEINS; PPAR GAMMA; TANDEM MASS SPECTROMETRY; THIAZOLIDINEDIONES; TISSUE DISTRIBUTION;

EID: 84924785693     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep09000     Document Type: Article

References (34)

1. Escribano, L. et al. Rosiglitazone rescues memory impairment in Alzheimer's transgenic mice: mechanisms involving a reduced amyloid and tau pathology. Neuropsychopharmacol. 35, 1593-1604 (2010).
2. Nicolakakis, N. et al. Complete rescue of cerebrovascular function in aged Alzheimer's disease transgenic mice by antioxidants and pioglitazone, a peroxisome proliferator-activated receptor gamma agonist. J. Neurosci. 28, 9287-9296 (2008).
3. Escribano, L. et al. Rosiglitazone reverses memory decline and hippocampal glucocorticoid receptor down-regulation in an Alzheimer's disease mouse model. Biochem. Biophys. Res. Commun. 379, 406-410 (2009).
4. Rodriguez-Rivera, J., Denner, L. & Dineley, K. T. Rosiglitazone reversal of Tg2576 cognitive deficits is independent of peripheral gluco-regulatory status. Behav. Brain Res. 216, 255-261 (2011).
5. Papadopoulos, P., Rosa-Neto, P., Rochford, J. & Hamel, E. Pioglitazone improves reversal learning and exerts mixed cerebrovascular effects in a mouse model of Alzheimer's disease with combined amyloid-beta and cerebrovascular pathology. PloS One 8, e68612 (2013).
6. Jiang, Q., Heneka, M. & Landreth, G. E. The role of peroxisome proliferator-activated receptor-gamma (PPARgamma) in Alzheimer's disease: therapeutic implications. CNS Drugs 22, 1-14 (2008).
7. Mandrekar-Colucci, S. & Landreth, G. E. Nuclear receptors as therapeutic targets for Alzheimer's disease. Expert Opin. Ther. Targets 15, 1085-1097 (2011).
8. Strum, J. C. et al. Rosiglitazone induces mitochondrial biogenesis in mouse brain. J. Alzheimers Dis. 11, 45-51 (2007).
9. Morato, L. et al. Pioglitazone halts axonal degeneration in a mouse model of X-linked adrenoleukodystrophy. Brain 136, 2432-2443 (2013).
10. Chang, K. L. et al. Metabolic Profiling of CHO-AbetaPP695 Cells Revealed Mitochondrial Dysfunction Prior to Amyloid-beta Pathology and Potential Therapeutic Effects of Both PPARgamma and PPARalpha Agonisms for Alzheimer's Disease. J. Alzheimers Dis. 44, 215-231 (2015).
11. Kornmann, B. Quality control in mitochondria: use it, break it, fix it, trash it. F1000Prime Rep. 6, 15 (2014).
12. Osellame, L. D. & Duchen, M. R. Quality control gone wrong: mitochondria, lysosomal storage disorders and neurodegeneration. Br. J. Pharmacol. 171, 1958-1972 (2014).
13. Watson, G. S. et al. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am. J. Geriat. Psychiat. 13, 950-958 (2005).
14. Risner, M. E. et al. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J. 6, 246-254 (2006).
15. Gold, M. et al. Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study. Dement. Geriatr. Cogn. Disord. 30, 131-146 (2010).
16. Schinkel, A. H. P-Glycoprotein, a gatekeeper in the blood-brain barrier. Adv. Drug Deliver. Rev. 36, 179-194 (1999).
17. Bauer, B., Hartz, A. M. & Miller, D. S. Tumor necrosis factor alpha and endothelin-1 increase P-glycoprotein expression and transport activity at the blood-brain barrier. Mol. Pharmacol. 71, 667-675 (2007).
18. Maeshiba, Y. et al. Disposition of the new antidiabetic agent pioglitazone in rats, dogs, and monkeys. Arzneim.-Forsch. 47, 29-35 (1997).
19. Sastre, M. et al. Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma. P. Natl. Acad. Sci. USA 103, 443-448 (2006).
20. Geldmacher, D. S., Fritsch, T., McClendon, M. J. & Landreth, G. A randomized pilot clinical trial of the safety of pioglitazone in treatment of patients with Alzheimer disease. Arch. Neurol. 68, 45-50 (2011).
21. Hanyu, H., Sato, T., Kiuchi, A., Sakurai, H. & Iwamoto, T. Pioglitazone improved cognition in a pilot study on patients with Alzheimer's disease and mild cognitive impairment with diabetes mellitus. J. Am. Geriatr. Soc. 57, 177-179 (2009).
22. Sato, T. et al. Efficacy of PPAR-gamma agonist pioglitazone in mild Alzheimer disease. Neurobiol. Aging 32, 1626-1633 (2011).
23. Takeda. Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2013 Dec 03]. Available from: http://clinicaltrials.gov/show/NCT01931566 NLM Identifier, NCT01931566. (2013).
24. Weiss, J. et al. Interaction of thiazolidinediones (glitazones) with the ATP-binding cassette transporters P-glycoprotein and breast cancer resistance protein. Pharmacology 84, 264-270 (2009).
25. Choong, E., Dobrinas, M., Carrupt, P. A. & Eap, C. B. The permeability P-glycoprotein: a focus on enantioselectivity and brain distribution. Expert Opin. Drug Metab. Toxicol. 6, 953-965 (2010).
26. Miura, M. & Uno, T. Clinical pharmacokinetics of fexofenadine enantiomers. Expert Opin. Drug Metab. Toxicol. 6, 69-74 (2010).
27. Takeda, S., Sato, N. & Morishita, R. Systemic inflammation, blood-brain barrier vulnerability and cognitive/non-cognitive symptoms in Alzheimer disease: relevance to pathogenesis and therapy. Front. Aging Neurosci. 6, 171 (2014).
28. Caserta, M. T., Caccioppo, D., Lapin, G. D., Ragin, A. & Groothuis, D. R. Blood-brain barrier integrity in Alzheimer's disease patients and elderly control subjects. J. Neuropsychiatry Clin. Neurosci. 10, 78-84 (1998).
29. van Assema, D. M. et al. No evidence for additional blood-brain barrier P-glycoprotein dysfunction in Alzheimer's disease patients with microbleeds. J. Cereb. Blood Flow Metab. 32, 1468-1471 (2012).
30. Swanson, C. R. et al. The PPAR-gamma agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys. J. Neuroinflammation 8, 91 (2011).
31. Saneja, A., Khare, V., Alam, N., Dubey, R. D. & Gupta, P. N. Advances in P-glycoprotein-based approaches for delivering anticancer drugs: pharmacokinetic perspective and clinical relevance. Expert Opin. Drug Delivery 11, 121-138 (2014).
32. Rochester, U. Pioglitazone in Early Parkinson's Disease. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2014 July 31].Available from: http://clinicaltrials.gov/show/NCT01280123 NLM Identifier, NCT01280123. (2013).
33. Choo, E. F. et al. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab. Disposit. 28, 655-660 (2000).
34. Wanek, T. et al. A novel PET protocol for visualization of breast cancer resistance protein function at the blood-brain barrier. J. Cereb. Blood Flow Metab 32, 2002-2011 (2012).